MEGF8: A Drug Target / Disease Biomarker (G1954)

Target Name: MEGF8

NCBI ID: G1954

MEGF8

MEGF8: A Drug Target / Disease Biomarker

MEGF8, also known as miR-202, is a non-coding RNA molecule that has been shown to play a critical role in the development and progression of various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed new light on its potential as a drug.

Mutations in the MEGF8 gene have been linked to a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its expression has also been shown to be regulated by a variety of factors, including DNA damage, cellular stress, and environmental factors.

One of the most promising aspects of MEGF8 is its potential as a drug target. The use of small molecules, such as drugs that bind to specific RNA structures, has been shown to be an effective way to target and regulate gene expression in a variety of organisms. By inhibiting the activity of MEGF8, researchers may be able to reduce the risk of disease associated with its high expression levels.

In addition to its potential as a drug target, MEGF8 has also been shown to be a valuable biomarker for a number of diseases. Its expression has been associated with a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. By detecting the expression of MEGF8 in biological samples, researchers may be able to diagnose and monitor the progression of these diseases.

One of the most promising applications of MEGF8 as a biomarker is its potential to detect cancer at an early stage. Its expression has been shown to be highly elevated in the tissues of cancer patients, making it an attractive target for cancer diagnostics. In addition, its expression has also been associated with the development of various types of cancer, including breast, ovarian, and prostate cancers.

In addition to its potential as a drug and biomarker, MEGF8 has also been shown to play a critical role in the regulation of cellular processes. Its expression has been shown to be regulated by a variety of factors, including DNA damage, cellular stress, and environmental factors. These regulation mechanisms may have implications for the development of new treatments for a variety of diseases.

In conclusion, MEGF8 is a non-coding RNA molecule that has been shown to play a critical role in the development and progression of various diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed new light on its potential as a drug and biomarker. Further research is needed to fully understand its mechanisms of action and its potential as a therapeutic agent.

Protein Name: Multiple EGF Like Domains 8

Functions: Acts as a negative regulator of hedgehog signaling

The "MEGF8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEGF8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets